Drug Insight: Aminosalicylates for the treatment of IBD

Ole H. Nielsen; Lars K. Munck

doi:10.1038/ncpgasthep0696

Drug Insight: Aminosalicylates for the treatment of IBD

Ole H. Nielsen^*, Lars K. Munck

^*Corresponding author af dette arbejde

Institut for Klinisk Medicin

102 Citationer (Scopus)

Abstract

Sulfasalazine and mesalazine (also known as mesalamine; 5-aminosalicylic acid) preparations have for many years been used for the treatment of IBD (i.e. ulcerative colitis and Crohn's disease), for both active disease and the control of remission. It has also been suggested that mesalazine is a chemoprophylactic agent that protects against the development of colorectal cancer. This Review focuses on the latest clinical evidence for the use of these aminosalicylates for the treatment of IBD, and concludes that sulfasalazine and mesalazine are useful for the treatment of both active and quiescent ulcerative colitis, whereas they have no clinical effect on either active or inactive Crohn's disease. Furthermore, evidence is lacking that mesalazine per se is a chemoprophylactic agent.

Originalsprog	Engelsk
Tidsskrift	Nature Clinical Practice Gastroenterology and Hepatology
Vol/bind	4
Udgave nummer	3
Sider (fra-til)	160-170
Antal sider	11
ISSN	1743-4378
DOI	https://doi.org/10.1038/ncpgasthep0696
Status	Udgivet - 1 mar. 2007

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1038/ncpgasthep0696

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{1510cefdb619407686a2f5d20355fba8,

title = "Drug Insight: Aminosalicylates for the treatment of IBD",

abstract = "Sulfasalazine and mesalazine (also known as mesalamine; 5-aminosalicylic acid) preparations have for many years been used for the treatment of IBD (i.e. ulcerative colitis and Crohn's disease), for both active disease and the control of remission. It has also been suggested that mesalazine is a chemoprophylactic agent that protects against the development of colorectal cancer. This Review focuses on the latest clinical evidence for the use of these aminosalicylates for the treatment of IBD, and concludes that sulfasalazine and mesalazine are useful for the treatment of both active and quiescent ulcerative colitis, whereas they have no clinical effect on either active or inactive Crohn's disease. Furthermore, evidence is lacking that mesalazine per se is a chemoprophylactic agent.",

author = "Nielsen, {Ole H.} and Munck, {Lars K.}",

year = "2007",

month = mar,

day = "1",

doi = "10.1038/ncpgasthep0696",

language = "English",

volume = "4",

pages = "160--170",

journal = "Nature Clinical Practice Gastroenterology and Hepatology",

issn = "1743-4378",

publisher = "nature publishing group",

number = "3",

}

TY - JOUR

T1 - Drug Insight

T2 - Aminosalicylates for the treatment of IBD

AU - Nielsen, Ole H.

AU - Munck, Lars K.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Sulfasalazine and mesalazine (also known as mesalamine; 5-aminosalicylic acid) preparations have for many years been used for the treatment of IBD (i.e. ulcerative colitis and Crohn's disease), for both active disease and the control of remission. It has also been suggested that mesalazine is a chemoprophylactic agent that protects against the development of colorectal cancer. This Review focuses on the latest clinical evidence for the use of these aminosalicylates for the treatment of IBD, and concludes that sulfasalazine and mesalazine are useful for the treatment of both active and quiescent ulcerative colitis, whereas they have no clinical effect on either active or inactive Crohn's disease. Furthermore, evidence is lacking that mesalazine per se is a chemoprophylactic agent.

AB - Sulfasalazine and mesalazine (also known as mesalamine; 5-aminosalicylic acid) preparations have for many years been used for the treatment of IBD (i.e. ulcerative colitis and Crohn's disease), for both active disease and the control of remission. It has also been suggested that mesalazine is a chemoprophylactic agent that protects against the development of colorectal cancer. This Review focuses on the latest clinical evidence for the use of these aminosalicylates for the treatment of IBD, and concludes that sulfasalazine and mesalazine are useful for the treatment of both active and quiescent ulcerative colitis, whereas they have no clinical effect on either active or inactive Crohn's disease. Furthermore, evidence is lacking that mesalazine per se is a chemoprophylactic agent.

UR - http://www.scopus.com/inward/record.url?scp=33847707327&partnerID=8YFLogxK

U2 - 10.1038/ncpgasthep0696

DO - 10.1038/ncpgasthep0696

M3 - Review

C2 - 17339853

AN - SCOPUS:33847707327

SN - 1743-4378

VL - 4

SP - 160

EP - 170

JO - Nature Clinical Practice Gastroenterology and Hepatology

JF - Nature Clinical Practice Gastroenterology and Hepatology

IS - 3

ER -

Drug Insight: Aminosalicylates for the treatment of IBD

Abstract

FN’s Verdensmål

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater